Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 11, Pages 1791-1804
Publisher
Springer Science and Business Media LLC
Online
2019-10-17
DOI
10.1007/s00262-019-02411-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab
- (2019) M. Christina Cox et al. CLINICAL CANCER RESEARCH
- Follicular lymphoma: 2018 update on diagnosis and management
- (2018) Arnold Freedman AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
- (2018) Marzia Palma et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
- (2017) Manh-Cuong Vo et al. EXPERIMENTAL HEMATOLOGY
- Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
- (2017) Abhishek D. Garg et al. TRENDS IN IMMUNOLOGY
- Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
- (2017) Manh-Cuong Vo et al. Oncotarget
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy
- (2017) B. Montico et al. OncoImmunology
- Dendritic Cell Therapies for Hematologic Malignancies
- (2017) Matthew Weinstock et al. Molecular Therapy-Methods & Clinical Development
- Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab.
- (2017) N. Aqui et al. JOURNAL OF CLINICAL ONCOLOGY
- Follicular lymphoma: evolving therapeutic strategies
- (2016) B. S. Kahl et al. BLOOD
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial
- (2016) Clémentine Sarkozy et al. JOURNAL OF CLINICAL ONCOLOGY
- NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients
- (2016) Caterina Lapenta et al. JOURNAL OF IMMUNOLOGY
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
- (2015) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
- (2015) E. A. Chong et al. CLINICAL CANCER RESEARCH
- Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
- (2015) Thanh-Nhan Nguyen-Pham et al. JOURNAL OF IMMUNOTHERAPY
- Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
- (2015) Carmela Rozera et al. Journal of Translational Medicine
- The Role of Angiogenesis in Human Non-Hodgkin Lymphomas
- (2015) Domenico Ribatti et al. NEOPLASIA
- Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
- (2014) Arne Kolstad et al. BLOOD
- Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
- (2014) A. Busch et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas
- (2013) Tahamtan Ahmadi et al. CANCER
- Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma
- (2013) K. Song et al. CANCER RESEARCH
- The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity
- (2013) Patricia Amé-Thomas et al. SEMINARS IN CANCER BIOLOGY
- Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays
- (2013) Iole Macchia et al. Biomed Research International
- Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis
- (2012) Frédéric Mourcin et al. Frontiers in Immunology
- IFN- enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing
- (2011) F. Spadaro et al. BLOOD
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
- (2011) E. Kneppers et al. BLOOD
- Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
- (2011) Bang-Ning Lee et al. CANCER
- Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling
- (2011) G Epron et al. LEUKEMIA
- Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma
- (2011) Karthick Raja Muthu Raja et al. LEUKEMIA & LYMPHOMA
- Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12
- (2011) Stefano M. Santini et al. PLoS One
- IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity
- (2010) Laura Lattanzi et al. IMMUNOBIOLOGY
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
- (2009) A. G. Ramsay et al. BLOOD
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
- (2009) M Lioznov et al. BONE MARROW TRANSPLANTATION
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
- Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
- (2008) M. Di Nicola et al. BLOOD
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
- (2008) A. Tzankov et al. HAEMATOLOGICA
- Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells
- (2008) M C Minnema et al. LEUKEMIA
- The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
- (2008) Ling Lu et al. MICROVASCULAR RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started